v3.25.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2025
Revenue  
Schedule of revenue recognized from collaborative arrangements

Three Months Ended March 31, 

(In thousands)

2025

2024

Viatris collaboration agreement – Amounts receivable from Viatris

$

15,388

$

14,503

Three Months Ended March 31, 

(In thousands)

  

2025

  

2024

YUPELRI net sales (Theravance Biopharma implied 35%)

$

20,420

$

19,329